<div id="readability-page-1"><p>Northland Securities analyst Carl Byrnes maintained a Buy rating on Connect Biopharma Holdings today and set a price target of $7.50.</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Byrnes covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Spectral AI, and Avita Medical. According to TipRanks, Byrnes has an average return of <span>-4.7%</span> and a 35.65% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Connect Biopharma Holdings with a $8.38 average price target.</p></div>

CNTB

SBIO

LABU

IBBQ

<p>Northland Securities analyst Carl Byrnes has maintained a Buy rating on Connect Biopharma Holdings (CNTB) with a price target of $7.50. The overall analyst consensus for CNTB is a Strong Buy, with an average price target of $8.38. Byrnes focuses on the Healthcare sector and has an average return of -4.7% with a 35.65% success rate on his stock recommendations.</p>

Tip Ranks

Connect Biopharma

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

BioLife Solutions

Spectral AI

Avita Medical

SPECTRAL AI INC C/WTS 11/09/2028(TO PUR COM)

Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)